Mutant TP53 promotes invasion of lung cancer cells by regulating desmoglein 3.

ABSTRACT:

Purpose

Targeted therapies have markedly improved the prognosis of lung cancer patients; nevertheless, challenges persist, including limited beneficiary populations and the emergence of drug resistance. This study investigates the molecular mechanisms of mutant TP53 in lung cancer, aiming to contribute to novel strategies for targeted therapy.

Methods

The TCGA database was employed to delineate the mutational landscape of TP53 in lung cancer patients. Differential gene expression between TP53-mutant and wild-type patients was analyzed, followed by functional enrichment. DSG3 protein expression in lung cancer patients was assessed using IHC, and its impact on prognosis was analyzed in the TCGA database. The influence of TP53 on the downstream gene DSG3 was investigated using

SUBMITTER: Feng Y 

PROVIDER: S-EPMC11189974 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature